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Introduction
Upon recognizing pathogen-associated molecular patterns, the 
family of 11 Toll-like receptors (TLRs) provides the initial acti-
vation signal to the immune system, resulting in costimulatory 
molecule expression and cytokine secretion (Krieg, 2002a; 
Takeda et al., 2003). These cytokines can modulate the adaptive 
immune response to eliminate particular classes of pathogens 
by polarizing CD4
+ T cells to either a Th1 or -2 phenotype 
(Krieg, 2002b). However, an unbalanced or sustained Th1 or -2 
response can lead to diseases such as rheumatoid arthritis and 
asthma (Trinchieri, 2003).
The pathogen-associated molecular pattern of unmethyl-
ated bacterial DNA is specifi  cally recognized by TLR9, and its 
immunomodulatory effects can be mimicked by oligodeoxy-
nucleotides (ODNs) containing unmethylated deoxycytidyl-
  deoxyguanosine (CpG) motifs (CpG-ODN; Krieg, 2002b). 
TLR9, expressed by B cells, macrophages, and dendritic cells 
(DCs), recognizes CpG in the acidic environment of the 
endosome (Ahmad-Nejad et al., 2002). Variant sequences fl  ank-
ing the stimulatory CpG core motif have been described for 
  optimal TLR9 activation expressed by specifi  c cell types. 
  Depending on the   cytokines secreted, those ODNs have been 
categorized as A, B, or C class ODNs; however, it remains 
 unclear  why  specifi  c CpG   sequences trigger different biological 
effects (Krieg, 2002b).
Studies using fl  uorescently labeled ODNs indicate that both 
stimulatory and nonstimulatory ODNs are internalized nonspe-
cifi  cally, but only stimulatory ODNs activate TLR9 in endosomes, 
where both ligand and receptor colocalize (Hacker et al., 1998; 
Latz et al., 2004; Leifer et al., 2004; Takeda and Akira, 2005). 
Uptake of ODN is dependent on dose, time, and temperature but 
independent of the CpG motif (Guo and Schluesener, 2004).
Upon recognition of CpG-rich sequences in the endo-
some, TLR9 initiates a conserved TLR family signaling cascade 
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T
oll-like receptors (TLRs) recognize molecular patterns 
preferentially expressed by pathogens. In endo-
somes, TLR9 is activated by unmethylated bacterial 
DNA, resulting in proinﬂ  ammatory cytokine secretion via 
the adaptor protein MyD88. We demonstrate that CpG 
oligonucleotides activate a TLR9-independent pathway 
initiated by two Src family kinases, Hck and Lyn, which 
trigger a tyrosine phosphorylation–mediated signaling 
cascade. This cascade induces actin cytoskeleton reorga-
nization, resulting in cell spreading, adhesion, and motility. 
CpG-induced actin polymerization originates at the plasma 
membrane, rather than in endosomes. Chloroquine, an 
  inhibitor of CpG-triggered cytokine secretion, blocked 
TLR9/MyD88-dependent cytokine secretion as expected 
but failed to inhibit CpG-induced Src family kinase activa-
tion and its dependent cellular responses. Knock down of Src 
family kinase expression or the use of speciﬁ  c kinase inhi-
bitors blocked MyD88-dependent signaling and cytokine 
secretion, providing evidence that tyrosine phosphoryl-
ation is both CpG induced and an upstream requirement 
for the engagement of TLR9. The Src family pathway inter-
sects the TLR9–MyD88 pathway by promoting the tyrosine 
phosphorylation of TLR9 and the recruitment of Syk   to 
this receptor.
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that begins with the recruitment of the adaptor protein MyD88 
via the Toll/interleukin (IL) 1 receptor domain (Ahmad-Nejad 
et al., 2002). MyD88 then recruits IL-1 receptor–associated 
kinase   (IRAK) 1 and 4 (Wesche et al., 1997). When phosphory-
lated by IRAK-4, IRAK-1 interacts with TRAF6 (TNF receptor–
associated factor 6; Cao et al., 1996; Li et al., 2002) and 
disengages from the receptor. A complex consisting of TRAF6, 
TAK1 (TGFβ-activated kinase 1), and TAB (TAK1 binding 
protein) 1 and 2 goes on to activate the IκB kinase complex, 
  resulting in nuclear factor (NF) κB translocation to the nucleus 
(Mercurio et al., 1997; Regnier et al., 1997; Jiang et al., 2003). 
CpG-induced NF-κB activation initiates the up-regulation of 
  costimulatory molecules and the secretion of proinfl  am  matory 
cytokines, such as TNFα and IL-6.
The adaptor protein MyD88 plays a crucial role in trans-
ducing signals from TLR family members. Upon binding to 
TLR4, bacterial lipopolysaccharide not only activates NF-κB via 
the MyD88–IRAK serine/threonine kinase pathway but also 
  induces tyrosine phosphorylation in macrophages (Weinstein 
et al., 1991). Two Src family kinases (SFKs), Hck and
Lyn, are responsible for initiating this pathway (English et al., 
1993; Beaty et al., 1994). Hck has been shown to regulate 
  differentiation and several actin-dependent processes such as 
F-actin–based membrane protrusions (Carreno et al., 2002), 
monocyte chemotaxis (Resnati et al., 1996; Chiaradonna et al., 
1999), phagocytosis (Suzuki et al., 2000; Le Cabec et al., 
2002), and cellular adhesion (Suen et al., 1999; Scholz et al., 
2000). In the well-characterized system of Fcγ receptor signal-
ing, Hck and Lyn are the initiating tyrosine kinases that phos-
phorylate immunoreceptor tyrosine-based activation motifs 
(ITAMs) in the signaling chains of the receptor complex, which 
then serve as docking sites for a second tier of tyrosine kinases 
such as Syk (Bolen and Brugge, 1997). Both Src and Syk 
family   kinases phosphorylate several downstream signaling 
Figure 1. SFKs initiate a chloroquine-
insensitive, CpG-triggered tyrosine phosphoryl-
ation cascade. (A) THP-1 monocytes were 
stimulated with a control ODN, GpC (lanes 
1–3),  and CpG–ODN 2216 (lanes 4–6) at 
1 μg/ml for the indicated times. 50-μg ali-
quots of lysate were subjected to SDS-PAGE 
followed by immunoblotting with an anti-pTyr 
antibody. Loading controls were immunoblotted 
with an anti-actin antibody. (B) Individual phos-
phoproteins were immunoprecipitated with 
the indicated antibodies from 100 μg of GpC- 
or CpG-stimulated (3 min) cell lysate and 
then   immunoblotted with anti-pTyr antibody. 
(C) THP-1 cells were pretreated for 30 min with 
  vehicle (lanes 1–3), 10 μM chloroquine (lanes 
4–6), 1 μM quinacrine (lanes 7–9), 1 μM of 
the SFK inhibitor PP2 (lanes 10–13), and 
1 μM of the control inhibitor PP3 (lanes 13–15). 
Lysates were prepared after CpG stimulation 
and   immunoblotted with anti-pTyr antibody.A NEW CPG-INDUCED TLR9-INDEPENDENT PATHWAY • SANJUAN ET AL. 1059
proteins and thus initiate multiple signaling events. It has 
  recently been reported that CpG-ODN stimulation induces 
  tyrosine phosphorylation of the GTP exchange factor Vav1 
(Stovall et al., 2004).
The TLR9 inhibitor chloroquine and analogues such as 
quinacrine inhibit immune stimulation by bacterial DNA and 
CpG-ODN (Macfarlane and Manzel, 1998; Strekowski et al., 
1999). The inhibition of TLR9 occurs at endosomes where 
chloroquine was shown to block CpG and TLR9 interaction 
(Rutz et al., 2004). Chloroquine (Trape et al., 2002) has also 
proven effective in the treatment of infl  ammatory diseases such 
as systemic lupus erythematosus and rheumatoid arthritis (Fox 
et al., 1987; Wallace, 2001; Araiza-Casillas et al., 2004; Nord 
et al., 2004).
We have investigated the role of SFKs upon CpG- induced 
TLR9 stimulation. Two SFKs, Hck and Lyn, are phosphorylated 
upon monocyte stimulation with CpG-ODN but not when cells
are treated with nonstimulatory deoxyguanosine-deoxycytidyl
(GpC) ODN. The SFK-initiated tyrosine phosphorylation cas-
cade activates signaling proteins implicated in reorganization of
the actin cytoskeleton, resulting in cell spreading, adhesion, and
motility. Surprisingly, the TLR9 inhibitor chloroquine failed 
to block SFK activation and any of the signaling pathways 
downstream of tyrosine kinase activation. Macrophages from 
TLR9
−/− and MyD88
−/− mice exhibited normal SFK activa-
tion, indicating that the SFK pathway is TLR9 independent. 
Unexpectedly, this pathway is triggered upstream of the 
traditional TLR9 pathway, as indicated by SFK inhibitors, 
which blocked CpG-induced phosphorylation of the NF-κB 
regulator IκB, IL-6 secretion, and up-regulation of CD40 and 
CD69. Both pathways intersect at the level of TLR9, which 
is tyrosine phosphorylated upon CpG stimulation and inter-
acts with the tyrosine kinase Syk. Furthermore, CpG-coated 
beads induce strong actin polymerization at the plasma 
membrane–bead contact area of macrophages in a chloro-
quine-insensitive manner. Together, these fi  ndings indicate 
that the SFK-driven tyrosine phosphorylation pathway is an 
early CpG-induced event that is initiated at the cell surface 
and is upstream of and required for TLR9/MyD88 activation 
in endosomes.
Results
CpG induces SFK activation
The role of SFKs after CpG-ODN treatment is unclear. To study 
the role of tyrosine kinases in TLR9 signaling, we stimulated the 
human monocyte cell line THP-1 with a control GpC and an ac-
tivating CpG-ODN. Cell lysates were then analyzed by immuno-
blotting with an anti-phosphotyrosine (pTyr) antibody. CpG 
treatment induced rapid tyrosine phosphorylation of multiple 
proteins, with maximum phosphorylation achieved 3 min after 
stimulation (Fig. 1 A, lanes 4–6). [ID]FIG1[/ID] The control non–CpG-ODN 
did not trigger tyrosine kinase activation (Fig. 1 A, lanes 1–3).
To specifi  cally identify phosphoproteins, candidate pro-
teins were immunoprecipitated and then immunoblotted with 
anti-pTyr antibody. Major phosphoproteins of 47, 52, 70, 95, 
120, and 125 kD were identifi  ed in this manner (Fig. 1 B). The 
three most prominent phosphoproteins identifi  ed were the cyto-
plasmic tyrosine kinase Syk (70 kD), the hematopoietic-specifi  c 
exchange factor Vav1 (95 kD), and the adaptor protein Cbl 
(120 kD). Two SFK members expressed in monocytic cells, Lyn 
(49 kD) and Hck (52 kD), were also phosphorylated upon CpG 
treatment. In addition, the hematopoietic-specifi  c focal adhe-
sion kinase Pyk2 (125 kD), talin (200 kD), paxillin (68 kD), and 
vinculin (117 kD) were also phosphorylated. However, other 
prominent B cell and macrophage tyrosine substrates, such as 
B cell linker protein and Bruton’s tyrosine kinase, were not 
phosphorylated upon CpG stimulation (unpublished data).
CpG-induced tyrosine 
phosphorylation is Src-kinase 
dependent but chloroquine insensitive
Because our results indicated that two SFKs, Hck and Lyn, were 
phosphorylated upon CpG treatment, we wanted to test whether 
an SFK inhibitor could block tyrosine phosphorylation. Pre-
treatment of THP-1 cells with PP2, a potent SFK inhibitor, 
completely blocked CpG-induced phosphorylation (Fig. 1 C, 
lanes 10–12). Pretreatment with PP3, an inactive version of 
PP2, had no effect on CpG-induced tyrosine phosphorylation 
(Fig. 1 C, lanes 13–15). Pretreatment with two well-described 
inhibitors of TLR9-induced cytokine production, chloroquine 
Figure 2.  Chloroquine fails to block CpG-
induced actin polymerization. Mouse 
  macrophages (RAW) or human monocytes 
(THP-1) were pretreated for 15 min with 
10 μM chloroquine (CQ) or vehicle control 
and then stimulated for 20 min with 1 μg/ml 
of the mouse-selective CpG–ODN 1668 or 
human CpG–ODN 2216, respectively. 
  After ﬁ  xation, cells were stained with FITC-
phalloidin (green) and nuclei were visual-
ized with TOPRO-3 (blue).JCB • VOLUME 172 • NUMBER 7 • 2006  1060
and quinacrine, also had no effect on CpG-induced tyrosine 
phosphorylation (Fig. 1 C, lanes 4–9).
CpG-induced actin cytoskeleton 
reorganization is chloroquine insensitive
SFK activation results in cytoskeleton changes and the tran-
scription of effector genes (Latour and Veillette, 2001). Six of 
the proteins that we found to be phosphorylated upon CpG 
stimulation, Pyk2, Vav, Cbl, talin, paxillin, and vinculin, along 
with the activation of PI3K, have been described as mediators of 
actin cytoskeleton reorganization (Suen et al., 1999; Caveggion 
et al., 2003; Chodniewicz and Zhelev, 2003; Tybulewicz et al., 
2003; Nayal et al., 2004; Mitra et al., 2005). These events 
promote cell spreading, adhesion, and motility, resulting in 
monocyte recruitment to areas of infection. When cells were 
stained for F-actin fi  bers, we found that CpG treatment induced 
strong actin polymerization in both mouse macrophages and 
human monocytes (Fig. 2). [ID]FIG2[/ID] These rearrangements translated to 
rapid cell spreading, conspicuous morphological changes, and 
increased cell size. In the case of THP-1 cells, CpG treatment 
induced the formation of actin-rich lamellipodia structures. 
Similar to CpG-induced tyrosine kinase phosphorylation (Fig. 1), 
the TLR9 inhibitor chloroquine was unable to block CpG-
induced actin reorganization (Fig. 2).
CpG induces the transient adhesion 
of monocytes
SFK-initiated actin reorganization can also facilitate cell 
  adhesion to promote the recruitment of cells to tissues infected 
by pathogens. Because CpG induced cytoskeleton reorganiza-
tion, we next tested the ability of CpG to induce monocyte 
  adhesion. When human monocytes were stimulated with CpG, 
they rapidly adhered in culture, with maximal adhesion de-
tected at 30 min (Fig. 3, A and C). [ID]FIG3[/ID] A negative control GpC-ODN 
failed to induce monocyte adhesion. Interestingly, a time-
course analysis of CpG-induced adhesion indicated that this 
event was transient, with cells detaching after 2 h (Fig. 3, A 
and C). Overnight culture of CpG-stimulated monocytes 
  revealed that cells eventually reattach, an event that we hypothe-
size is driven by secondary CpG-induced effects, such as 
Figure 3.  CpG-induced cell adhesion is insen-
sitive to chloroquine but requires SFK activity. 
(A) Cells were stimulated with 1 μg/ml of a 
control GpC-ODN or with CpG–ODN 2216 
for the indicated times (min). After ﬁ  xation, 
cells were visualized as described in Materials 
and methods. (B) THP-1 cells were preincu-
bated for 10 min with chloroquine, quinacrine, 
PP2, and PP3. The number at the lower right 
corner of each panel indicates the concentra-
tion for each inhibitor used (μM). Cells were 
then stimulated for 30 min with CpG, and ad-
hesion was measured. Representative ﬁ  elds 
are presented. (C) THP-1 cells were stimulated 
as indicated in A, and images captured from 
36 different ﬁ  elds from at least four different 
wells were quantiﬁ  ed to obtain cell number per 
ﬁ  eld and plotted with the SD. (D) THP-1 cells 
were stimulated for 20 min with increasing 
concentrations of CpG, control GpC, the B 
class oligo 2006 (ODN 2006), and murine 
CpG (mCpG), and adhesion was measured. 
(E) Adhesion was measured on THP-1 cells that 
were pretreated for 10 min with increasing 
concentrations of PP2, PP3, and herbimycin A 
and then stimulated with CpG for 30 min. 
Data are represented as percentage of ad-
hered cells versus vehicle-pretreated cells. 
(F) THP-1 cells were preincubated for 10 min 
with increasing concentrations of chloroquine 
or quinacrine. Cells were then stimulated for 
30 min with CpG, and the number of adhered 
cells from at least 36 different ﬁ  elds was quan-
tiﬁ  ed. Error bars indicate SD.A NEW CPG-INDUCED TLR9-INDEPENDENT PATHWAY • SANJUAN ET AL. 1061
chemokine secretion, because it can be blocked by chloroquine 
 (unpublished  data).
Next, we further characterized the ability of different 
CpG-ODNs to induce adhesion. We found that the human CpG-
ODN that induced robust tyrosine phosphorylation also induced 
adhesion in a concentration-dependent manner (Fig. 3 D). 
 Although  2  μg/ml CpG produced the highest level of adhesion, 
0.5 μg/ml was suffi  cient to induce signifi  cant adhesion (Fig. 3 D). 
A GpC control ODN or a mouse-selective CpG-ODN was 
  unable to induce signifi  cant cell adhesion at any concentration 
tested. Interestingly, when we compared the performance of 
an A class ODN with that of a B class ODN (ODN 2006), we 
found that the latter yielded a less pronounced adhesion re-
sponse (Fig. 3 D). This also correlated with a poor induction 
of the tyrosine phosphorylation cascade (unpublished data). 
  Although only immunostimulatory CpG promotes cytoskeleton 
rearrangement, it has been reported that both immunostimula-
tory and nonimmunostimulatory ODNs are internalized at the 
same rate in a time-, dose-, and temperature-dependent manner 
(Hacker et al., 1998; Guo and Schluesener, 2004; Takeda and 
Akira, 2005; unpublished data), indicating that CpG-induced 
SFK activation does not enhance ODN uptake. This is consis-
tent with our observations that PP2 treatment had no effect on 
CpG internalization (unpublished data).
Our previous experiments indicated that inhibition of SFKs 
blocked the phosphorylation of proteins that promote   cellular 
  adhesion, such as Pyk2 and Vav1 (Fig. 1). Based on these data, we 
hypothesized that the SFK inhibitor PP2 would also block mono-
cyte adhesion. When we tested this hypothesis, we found that 
PP2 potently blocked CpG-induced adhesion, even at concentra-
tions below the micromolar range (Fig. 3, B and E). As expected, 
the control inhibitor PP3 had no effect on monocyte adhesion. 
  Herbimycin A, another SFK inhibitor, also blocked monocyte 
 adhesion at submicromolar concentrations (Fig. 3 E). Actin-driven 
morphological changes are dynamic processes mediated by the 
polymerization and depolymerization of actin fi  bers. Therefore, 
we examined the effects of the actin microfi  lament–disrupting 
drugs cytochalasin D, latrunculin A, and jasplakinolide. All three 
inhibitors potently blocked monocyte adhesion at the nanomolar
range (Fig. S1, available at http://www.jcb.org/cgi/content/full/
jcb.200508058/DC1).   Together, these data indicated that CpG-
  triggered SFK activation initiates a tyrosine-kinase signaling 
  cascade in monocytes that results in actin-driven cytoskeleton 
changes that promote cell adhesion.
SFK-dependent cellular responses 
are chloroquine insensitive
Chloroquine blocks CpG interaction with TLR9 at the endo-
some (Rutz et al., 2004), and our previous fi  ndings indicated 
that although CpG-induced tyrosine kinase activation was 
blocked by the SFK inhibitor PP2, it was insensitive to chloro-
quine (Fig. 1 C). We therefore tested the ability of chloroquine 
and quinacrine to modulate CpG-induced adhesion. Even at 
high concentrations that completely inhibit TLR9-induced 
  cytokine production (10 μM for chloroquine and 1 μM for 
quinacrine), both inhibitors failed to block CpG-induced adhesion 
(Fig. 3, B and F).
To corroborate our fi   ndings using primary cells, we 
  repeated these studies using immature human DCs. Similar 
to a human monocytic cell line, CpG induced adhesion of 
human monocyte–derived DCs, whereas GpC did not (Fig. 
4 A). [ID]FIG4[/ID] In immature DCs, we found that SFK inhibitors are 
able to effectively block CpG-induced adhesion (Fig. 4 B). 
Although chloroquine and quinacrine blocked IFN-α secre-
tion from   peripheral blood mononuclear cells (PBMCs) at 
concentrations of <10 and 1 μM, respectively (Fig. 4 C), 
they were unable to block CpG-induced adhesion at similar 
concentrations (Fig. 4 B).
Figure 4.  CpG-induced chloroquine-insensitive adhesion of human DCs. 
(A) Adhesion was measured in human monocyte–derived immature DCs, 
as described in Fig. 3. Cells were stimulated with CpG–ODN 2216, and 
the number of adhered cells was obtained at the indicated times. White 
bars represent background adhesion, gray bars indicate adhesion in the 
presence of a control GpC-ODN, and black bars indicate adhesion in-
duced by CpG-ODN. Error bars indicate SD. (B) DCs were preincubated 
for 15 min with chloroquine (CQ; 10 μM), quinacrine (Qu; 1 μM), herbi-
mycin A (5 μM), PP2 (1 μM), and PP3 (1 μM). Cells were then stimulated 
with GpC and CpG-ODN, and adhesion was quantiﬁ  ed as previously 
described. (C) pDCs puriﬁ  ed from human PBMCs were incubated with the 
indicated concentrations of chloroquine and quinacrine in the presence 
of CpG for 18 h. Culture supernatants were analyzed for secreted IFN-α 
by ELISA.JCB • VOLUME 172 • NUMBER 7 • 2006  1062
Another prominent cytoskeleton-dependent process is cell 
motility. All of the identifi  ed CpG-induced phosphoproteins 
have been implicated in driving or regulating cell motility 
(Fig. 1 B). As previously described (Baek et al., 2001), we found 
that monocytes migrate toward a CpG gradient (Fig. S2, avail-
able at http://www.jcb.org/cgi/content/full/jcb. 200508058/DC1). 
As in the case of adhesion, chloroquine and quinacrine failed 
to block monocyte migration in response to CpG (Fig. S2).
CpG-triggered SFK activation is required 
for cytokine secretion
The secretion of CpG-induced infl  ammatory cytokines is de-
pendent on NF-κB translocation to the nucleus (Krieg, 2002b). 
The negative regulator of NF-κB activation, IκB-α, is phos-
phorylated and degraded after 5 min and remains strongly phos-
phorylated 45 min after CpG treatment (Fig. 5 A). [ID]FIG5[/ID] As expected, 
the TLR9 inhibitor chloroquine blocked IκB-α phosphorylation 
and degradation in monocytes (Fig. 5 A). Our previous results 
(Fig. 1) indicated that CpG-induced SFK activation precedes 
IκB-α phosphorylation and degradation, which are undetect-
able at 2.5 min as compared with maximal CpG-induced tyro-
sine phosphorylation at 3 min after CpG treatment. Given the 
rapid kinetics of SFK activation and insensitivity to chloroquine 
treatment, we hypothesized that CpG-induced tyrosine phos-
phorylation is upstream of IκB-α phosphorylation. When we 
tested this hypothesis in macrophages, we found that the SFK 
inhibitor PP2 effectively blocked IκB-α phosphorylation upon 
CpG stimulation (Fig. 5 B). Like chloroquine, the SFK inhibitor 
PP2 also inhibited CpG-induced IFN-α secretion in immature 
human plasmacytoid DCs (pDCs; Fig. 5 C). Furthermore, PP2 
effectively blocked CpG-induced IL-6 secretion (Fig. 5 D) and 
the up-regulation of B cell activation markers such as CD40 and 
CD69 (Fig. 5 E). To complement our pharmacological inhibitor 
data, we established a small interfering RNA (siRNA) system to 
specifi  cally knock down the expression of Lyn and Hck, two 
leukocyte SFKs that we identifi  ed as being activated by CpG. 
Immunoblot analysis of siRNA-transfected cell lysates revealed 
that an 80% knockdown of Lyn and a >90% knockdown of Hck 
was achieved (Fig. 6 A).  [ID]FIG6[/ID]When these cells were used in a CpG-
induced adhesion assay, single knockdown of Lyn or Hck re-
sulted in a signifi  cant decrease in cellular adhesion (Fig. 6 B). 
A combined knockdown of Lyn and Hck further decreased 
CpG-induced adhesion by  60%. The residual adhesion is most 
probably mediated by other SFKs, such as Blk, Fyn, and Src. 
Moreover, analysis of cytokine production revealed a similar 
trend, where combined knockdown of Lyn and Hck reduced 
CpG-induced TNFα production by  60% (Fig. 6 C). Together, 
both the pharmacological inhibitor and genetic data indicated 
that early activation of SFKs plays a key role in CpG-induced 
activation of monocytes.
CpG-triggered SFK activation 
is upstream of MyD88 and originates 
at the plasma membrane
The SFK pathway remains intact even when the TLR9– MyD88 
signaling pathway is blocked using chloroquine. Next, we used 
Figure 5.  CpG-induced SFK activation is upstream of NF-𝗋B activation. (A) Raw cells lysates were collected after CpG treatment (ODN 1585) in the 
  presence or absence of 10 μM chloroquine (CQ). IκB-α was immunoprecipitated, and the product was resolved by SDS-PAGE and immunoblotted with a 
phospho–IκB-α antibody. The degradation of IκB-α was also detected using an IκB-α antibody. (B) Cells were pretreated with the SFK inhibitor PP2 and its 
control PP3. Lysates were analyzed as described in A. (C) Isolated pDCs from human blood were cultured for 18 h and then preincubated for 15 min with 
vehicle or PP2 (2 μM). Cells were then stimulated with 5 μM CpG. After 24 h of culture, supernatants were taken and analyzed for type I interferon levels. 
(D) Splenocytes from B6 mice were pretreated for 1 h with increasing concentrations of PP2, PP3, and chloroquine and then stimulated with CpG for 
12 h. Supernatants were analyzed for IL-6 secretion by ELISA. Error bars indicate SD. (E) Splenocytes from D were analyzed for CpG-induced up-regulation 
of CD69 and CD40 by FACS. Unshaded versus shaded histogram for each panel represents the following: untreated versus CpG stimulated (top), and 
untreated versus CpG plus chloroquine treatment (middle). (bottom) B cells pretreated with PP2 (unshaded) versus PP3 (shaded) after CpG treatment.A NEW CPG-INDUCED TLR9-INDEPENDENT PATHWAY • SANJUAN ET AL. 1063
an alternative method to pharmacological inhibitors to confi  rm 
our results. Because the adaptor protein MyD88 is required for 
signal transduction downstream of TLR9, we decided to test 
whether the CpG-induced tyrosine phosphorylation cascade is 
intact in the absence of MyD88. The same intensity and kinetics 
of phosphorylation was observed in both control and MyD88
−/− 
macrophages stimulated with CpG-ODN (Fig. 7 A). [ID]FIG7[/ID] Consistent 
with our previous results, chloroquine treatment did not block 
CpG-induced tyrosine phosphorylation in either wild-type or 
MyD88
−/− macrophages (Fig. 7 A). Although the SFK pathway 
was intact in MyD88
−/− macrophages, CpG treatment was un-
able to induce translocation of the p65 subunit of NF-κB to the 
nucleus (Fig. 7 B). Consequently, NF-κB–driven responses such 
as the up-regulation of CD40 and CD69 and the secretion of IL-6 
were impaired in cells from MyD88
−/− mice (Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200508058/DC1).
Because our data indicated that the SFK pathway was 
activated at the cell surface, we decided to directly test this 
Figure 6.  Knockdown of SFK expression by siRNA signiﬁ  cantly inhibits 
CpG-induced adhesion and cytokine production. (A) THP-1 cells were 
transfected with control-scrambled siRNA or siRNA pools for Lyn, Hck, 
or both kinases and then cultured for 48 h. Gene knockdown was visu-
alized by immunoblotting lysates with anti-Lyn or anti-Hck antibodies. 
(B) Cells from A were stimulated with GpC control or CpG–ODN 2216 
(1 μM) for 20 min and tested in an adhesion assay, as described in 
Fig. 3 A. (C) THP-1 cells from A were plated at 5 × 10
5 cells/well in 
triplicate. Cells were stimulated with a GpC control or CpG–ODN 2216 
for 4 h. TNFα in culture supernatants was measured by ELISA. Error bars 
indicate SD.
Figure 7.  CpG activates SFKs at the plasma membrane and upstream of 
the MyD88 activation. (A) Thioglycollate-elicited peritoneal macrophages 
were obtained from wild-type and MyD88
−/− mice and cultured for 24 h 
in medium containing 0.5% FBS. Cells were pretreated with 10 μM chlo-
roquine (CQ) or vehicle for 15 min and stimulated with CpG–ODN 1585 
for 5 min. Tyrosine phosphorylation after CpG treatment was visualized by 
immunoblotting with an anti-pTyr antibody. (B) Murine bone marrow–
  derived DCs from wild-type and MyD88
−/− mice were pretreated with 
10 μM chloroquine or vehicle for 15 min, and after CpG stimulation, cells 
were stained with an antibody to the p65 subunit of NF-κB. (C) CpG- or 
GpC-coated 10-μm red ﬂ  uorescent polystyrene beads were added to RAW 
cells for 20 min. Cells were then ﬁ  xed and stained with FITC-phalloidin. 
The yellow arrow indicates the location of cells.JCB • VOLUME 172 • NUMBER 7 • 2006  1064
hypothesis by stimulating cells with CpG-ODN that are 
unable to be internalized. 10-μm red fl  uorescent polystyrene 
beads that are large enough to avoid internalization by macro-
phages were coated with CpG or control GpC-ODN. Upon 
incubating these beads with mouse macrophages for 20 min, 
we observed strong actin polymerization localized specifi  cally 
at the plasma membrane of the cell–bead contact area (Fig. 7 C). 
Beads coated with CpG, but not with the control GpC-ODN, 
specifi  cally induced this actin polymerization. Consistent with 
our previous fi  ndings, actin reorganization was chloroquine 
insensitive (Fig. 7 C).
The SFK pathway is TLR9 independent 
but intersects with the MyD88 pathway
It has recently been reported that CpG-induced Akt phosphoryla-
tion occurs via a TLR9-independent pathway (Dragoi et al., 
2005). It is possible that the chloroquine-insensitive SFK pathway 
that we describe originates at the plasma membrane in a TLR9-
independent manner, similar to that described for Akt phosphory-
lation. Once CpG is internalized into endosomes, it would interact 
with TLR9 and initiate the chloroquine-sensitive TLR9–MyD88 
pathway. To test this hypothesis, we stimulated TLR9
−/− macro-
phages with CpG and obtained a pattern of tyrosine phosphory-
lated proteins similar to that of wild-type macrophages, indicating 
that CpG-induced SFK activation is intact in cells lacking TLR9 
(Fig. 8 A). [ID]FIG8[/ID] Furthermore, the downstream actin cytoskeleton rear-
rangements were also unperturbed in cells from both TLR9
−/− 
and MyD88
−/− mice stimulated with CpG-coated beads (Fig. 8 B). 
These data indicate that this pathway is both TLR9 independent 
and initiated at the cell surface before CpG endocytosis. Although 
CpG recognition can happen before CpG internalization, as we 
show here, it has been demonstrated that CpG internalization is 
required for cell activation and cytokine production (Krieg et al., 
1995; Manzel and Macfarlane, 1999; Ahmad-Nejad et al., 2002). 
In accordance with these fi  ndings, plate-bound CpG was unable 
to induce IL-6 secretion (Fig. 8 C). Although the TLR9–MyD88 
pathway was impaired when CpG was immobilized, confocal 
analyses indicated that CpG-induced cytoskeletal rearrangements 
were intact (Fig. 8 D). Macrophages stimulated with CpG immo-
bilized on plastic generated large, actin-rich lamellipodia. Similar 
actin rearrangements were observed in macrophages from 
MyD88
−/− and TLR9
−/− mice (Fig. 8 D).
Figure 8.  CpG-induced SFK activation is a 
TLR9-independent event. (A) Thioglycollate-
  elicited peritoneal macrophages were obtained 
from wild-type (WT) and TLR9
−/− mice. After 
24 h of culture in medium (0.5% FCS), cells were   
stimulated with CpG–ODN 1585 for 5 and 
10 min.Tyrosine phosphorylation after CpG treat-
ment was visualized by immunoblotting with an 
anti-pTyr antibody. (B) Peritoneal macrophages 
  obtained from wild-type, MyD88
−/−, and 
TLR9
−/− mice were cultured for 24 h, and CpG- 
or GpC-coated 15-μm red ﬂ  uorescent polysty-
rene beads were added for 20 min. Cells were 
then ﬁ   xed and stained with FITC-phalloidin. 
(C) High-binding 96-well plates were coated with 
100 μl of a CpG solution for 15 h at 0.5 and 
1 μg/ml, and unbounded ODN were removed 
by washing thoroughly. Peritoneal macro-
phages were plated at 2 × 10
5 cells per well. 
A different group of cells was stimulated with 
soluble CpG at the indicated concentration. 
15 h later, supernatants were collected and se-
creted IL-6 was measured by ELISA. (D) Freshly 
isolated peritoneal macrophages were allowed 
to attach for only 10 min to wells previously 
covered with CpG and GpC. After paraformal-
dehyde ﬁ  xation, cells were stained with FITC-
phalloidin (green) and nuclei were visualized 
with TOPRO-3 (red). (E) Adhesion was assayed 
in THP-1 cells pretreated with wortmannin 
at increasing concentrations, as previously 
  described. (F) THP-1 cells were pretreated with 
10 μM chloroquine (CQ), 1 μM PP2, and 
1 μM wortmannin (W) for 20 min. After CpG 
stimulation for 5 min, the phosphorylation of 
Akt was analyzed by Western blot. (G) THP-1 
cells expressing Flag-TLR9 were pretreated with 
10 μM chloroquine and 1 μM PP2 for 20 min. 
After stimulating the cells for 5 min, samples 
were lysed and TLR9 was immunoprecipitated 
using an anti-Flag antibody. Flag-TLR9 and Syk 
were then detected by Western blot. (H) Cells 
were pretreated as before and also with Syk 
inhibitor (SI). Immunoprecipitated TLR9 was 
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Next, we examined whether the CpG-induced SFK path-
way is upstream of the previously described TLR9-independent 
phosphorylation of Akt (Dragoi et al., 2005). Activation of 
SFKs promotes actin reorganization through the participation of 
PI3K, an upstream regulator of Akt (Franke et al., 1997). Treat-
ment of cells with the PI3K inhibitor wortmannin inhibited both 
CpG-induced cell adhesion (Fig. 8 E) and phosphorylation of 
Akt (Fig. 8 F). Furthermore, use of the SFK inhibitor PP2 
blocked CpG-induced Akt phosphorylation (Fig. 8 F), indicat-
ing that the SFK pathway is upstream of the previously reported 
TLR9-independent phosphorylation of Akt.
Given that the CpG-induced SFK pathway originates at the 
plasma membrane and TLR9 is itself located in endosomes, we 
next wanted to investigate how these two pathways   intersect. 
  Recently, Syk, a CpG-activated kinase that we identifi  ed (Fig. 1), 
was reported to be a key component in the innate response to 
  zymosan (Rogers et al., 2005). Syk was shown to couple to the 
β-glucan receptor Dectin-1 and work synergistically with TLR2 
to mount an immune response to zymosan. Using a THP-1 cell 
line expressing a Flag-tagged TLR9, we found that upon CpG 
stimulation Syk coimmunoprecipitates with TLR9 (Fig. 8 G). 
This interaction provides a link between the SFK pathway and 
the MyD88 pathway. This interaction is unperturbed in the pres-
ence of the TLR9 inhibitor chloroquine, suggesting that it occurs 
before the generation of a signal through TLR9. Both the SFK in-
hibitor PP2 and a specifi  c Syk inhibitor blocked the interaction 
of Syk with TLR9. To further examine the association of Syk 
with TLR9, we examined whether TLR9 itself was tyrosine 
phosphorylated. CpG treatment did indeed induce   tyrosine phos-
phorylation of TLR9 (Fig. 8 H). Consistent with our previous ex-
periments, this event was chloroquine   insensitive but completely 
blocked by PP2 and partially blocked with a Syk inhibitor.
Discussion
CpG-containing ODNs activate TLR9 in endosomes and trigger 
the secretion of infl  ammatory cytokines by a mechanism that is 
dependent on the adaptor protein MyD88 (Krieg, 2002b; Takeda 
et al., 2003). We demonstrate that cellular activation by immuno-
stimulatory ODNs is more complex than previously described 
and requires a TLR9-independent SFK-driven pathway. This 
SFK-dependent signaling cascade is not parallel but upstream 
of the chloroquine-sensitive TLR9–MyD88 pathway.
We fi rst provide evidence that stimulation with CpG, but 
not the control GpC, induces a complex pattern of tyrosine 
phosphorylation in monocytes. While characterizing several 
of these phosphorylated proteins, we identifi  ed two SFKs ex-
pressed in myeloid cells, Hck and Lyn. Treatment of monocytes 
with the SFK inhibitor PP2 inhibited the CpG-induced tyrosine 
phosphorylation cascade. Interestingly, treatment with chloro-
quine and quinacrine, two known inhibitors of TLR9 signaling, 
failed to block tyrosine phosphorylation.
In addition to the kinases Hck and Lyn, we found that 
CpG also induced the phosphorylation of Pyk2, Cbl, and the 
previously described CpG-activated Vav (Stovall et al., 2004). 
These proteins are required for adhesion and migration re-
sponses that involve rearrangement of the actin cytoskeleton 
(Suzuki et al., 2000; Latour and Veillette, 2001). For example, 
the phosphorylation of Pyk2 by SFKs, along with the participa-
tion of other focal adhesion proteins, promotes actin cytoskele-
ton rearrangements that induce cell adhesion, spreading, and 
lamellipodia formation (Suen et al., 1999). Cbl, which interacts 
with Pyk2, Vav, and SFKs, has been associated with increased 
motility of macrophages (Caveggion et al., 2003). Vav, a multi-
domain signal integrator, transduces signals to cytoskeleton-
dependent pathways, which include the PI3K pathway and the 
activation of extracellular signal–regulated kinase and NF-κB 
(Tybulewicz et al., 2003). The phosphorylation of Pyk2, Cbl, 
and Vav upon CpG stimulation suggested that actin reorganiza-
tion plays an important role upon CpG stimulation. Indeed, 
our experiments confi  rmed that CpG triggered the reorganiza-
tion of the actin cytoskeleton, promoting cell adhesion and 
  migration. We found that CpG treatment induced a transient, 
SFK-dependent cell adhesion in human monocytes but not when 
cells were stimulated with either control GpC-ODN or a mouse-
selective CpG-ODN. Again, the TLR9 inhibitor chloroquine 
was unable to block CpG-induced adhesion and migration of 
THP-1 monocytes and adhesion on human monocyte–  derived 
DCs; however, those cellular responses were completely 
blocked with an SFK inhibitor.
CpG-induced SFK signaling was upstream and required 
for NF-κB activation and subsequent cytokine secretion. SFK 
inhibitors blocked CpG-induced secretion of IL-6 in spleno-
cytes, IFN-α production in human pDCs, and the up-regulation 
of activation markers on murine B cells. Furthermore, we found 
that SFK activation was intact in MyD88
−/− mice, indicating 
that this pathway is both upstream and independent of MyD88.
The rapid kinetics of tyrosine phosphorylation suggested 
that this event was initiated at the cell surface and independent 
of the endosomal localized TLR9. The use of CpG-coated 
beads, too large to be internalized, revealed that CpG induced 
robust, rapid actin reorganization at the bead–cell contact area, 
further suggesting that these events did not require internaliza-
tion of CpG. The use of TLR9
−/− and MyD88
−/− monocytes in-
dicated that these cellular events were independent of TLR9 and 
MyD88 in addition to being chloroquine insensitive. Together, 
these studies indicated that CpG-induced SFK activation at the 
plasma membrane drives cytoskeletal reorganization upstream 
and independently of the TLR9–MyD88 pathway that could re-
sult in cell adhesion and migration. In support of our fi  ndings, it 
was recently reported that, upon DNA viral infection of mice, 
leukocyte recruitment to the liver is not altered in TLR9
−/− and 
MyD88 
−/− mice, whereas the secretion of cytokines in vivo 
was dramatically reduced (Delale et al., 2005).
Our fi  ndings indicate that the recognition of CpG-ODN 
is more complex than previously described, but as reported 
(Krieg et al., 1995; Manzel and Macfarlane, 1999), this 
TLR9- independent pathway cannot induce cytokine secretion 
without ODN internalization. Although plate-bound CpG 
induced the formation of large lamellipodia in macrophages 
from wild-type, TLR9
−/−, and MyD88
−/− mice, it was unable 
to induce IL-6 secretion.
The TLR9 receptor responds differently to the three iden-
tifi  ed ODN classes (A, B, and C). The mechanism by which JCB • VOLUME 172 • NUMBER 7 • 2006  1066
these diversifi  ed responses are generated remains unresolved 
(Vollmer et al., 2004). It has been hypothesized that TLR9 re-
quires additional coreceptors/cofactors, as is the case for TLR4 
(Verthelyi and Zeuner, 2003), for the recognition of CpG–A 
class ODNs (Gursel et al., 2002). Our fi  ndings support this hypo-
thesis because SFK activation and downstream cellular events 
are most strongly triggered by CpG–A class ODN when com-
pared with B class ODN. Based on our preliminary character-
ization of this pathway, we hypothesize that a CpG-sensing 
coreceptor/cofactor is localized at the plasma membrane, which 
could also potentially be internalized with CpG-ODN, resulting 
in endosomal TLR9 activation (Fig. 9). [ID]FIG9[/ID] Until this pathway is 
further characterized, it remains possible that this coreceptor/
cofactor is also localized in the endosome in resting cells.
The role of PI3K family on TLR signaling is poorly 
  understood. PI3K interacts with the cytosolic Toll/IL-1 receptor 
domain of TLR2 (Arbibe et al., 2000) and has been found acti-
vated downstream of IRAK1 in response to IL-1β (Neumann 
et al., 2002). Recently, Akt, a downstream effector of the SFK–
PI3K pathway (Franke et al., 1997), was shown to be phosphor-
ylated in response to CpG by a TLR9-independent mechanism 
that involves DNA-dependent protein kinase (Dragoi et al., 
2005). In our experimental system, Akt phosphorylation was 
intact in chloroquine-treated cells, indicating that the MyD88 
cascade is not involved in Akt activation. However, Akt phos-
phorylation was completely blocked by both PP2 and the PI3K 
inhibitor wortmannin. These data indicate that the TLR9-
  independent tyrosine phosphorylation cascade that we describe 
is upstream of Akt activation.
Finally, we provide evidence that the SFK pathway does 
intersect with the TLR9–MyD88 pathway. TLR9 is tyrosine 
phosphorylated upon CpG stimulation, and this event is inde-
pendent of chloroquine but blocked by PP2. Furthermore, Syk 
coimmunoprecipitates with TLR9 upon CpG stimulation, and 
this interaction can be blocked by PP2. Because Syk is normally 
recruited to ITAM-containing receptors, which is not the case of 
TLR9, it is likely that the TLR9–Syk association is indirect and 
that other proteins participate in the formation of a complex. 
Two potential ITAM chains, the γ chain of the Fc receptor and 
DAP12 (DNAX-activating protein of 12 kD) were examined, 
but no phosphorylation was detected upon CpG stimulation 
(unpublished data). Although our experiments do not reveal 
whether Syk associates directly with TLR9, coimmunoprecipi-
tation after CpG stimulation is not affected by chloroquine, in-
dicating that this event is driven by the initial SFK pathway 
independently of TLR9. This link between tyrosine kinase sig-
naling and TLRs is further supported by a recent study involv-
ing TLR3, a receptor for double-stranded RNA. Like TLR9, 
TLR3 is tyrosine phosphorylated, and this event is linked to 
PI3K-mediated enhancement of the interferon regulatory factor 3 
pathway (Sarkar et al., 2004). Unlike our fi  ndings with TLR9, 
TLR3 phosphorylation does not regulate NF-κB activation.
In conclusion, we describe a TLR9-independent, SFK-
driven signaling cascade induced by CpG. This cascade is 
  upstream of the MyD88-dependent endosomal pathway and is 
initiated at the plasma membrane. This chloroquine-insensitive 
pathway initiates complex cytoskeletal rearrangements neces-
sary for cell biological events such as adhesion and migration. 
Moreover, these two pathways interact, as inhibition of the SFK 
pathway blocks activation events downstream of endosomal 
TLR9/MyD88 such as NF-κB activation and cytokine secretion. 
Our fi  ndings suggest that a potential CpG-sensing receptor is 
localized at the plasma membrane and might interact with CpG 
before the activation of endosomal TLR9. Future studies are re-
quired to identify candidate proteins that would perform this 
function. The identifi  cation of a TLR9 coreceptor would poten-
tially provide a new target for pharmaceutical intervention that 
could result in new treatments for autoimmune diseases.
Materials and methods
Cells
THP-1 and RAW264.7 (RAW) cells were obtained from American Type 
Culture Collection and cultured in RPMI 1640 medium (Invitrogen) supple-
mented with 10% FCS (Invitrogen), 2 mM L-glutamine, and antibiotics. 
Flag-TLR9 stable transfected THP-1 were selected after transfecting THP-1 
with NH2-terminal–tagged version of hTLR9 cloned in p3× Flag-CMV-9, 
where original TLR9 leader peptide was replaced by the one provided in 
the vector. TLR9
−/− and MyD88
−/− mice were provided by S. Akira (Osaka 
University, Suita, Japan). Single-cell spleen suspensions from wild-type 
(C57BL/6 background) and MyD88
−/− mice were obtained after mincing 
spleens and lysing erythrocytes. Cells were then cultured in RPMI 1640 
medium supplemented with 10% FCS. Human monocyte–derived DCs were 
derived from human peripheral blood as previously described (Vincent 
et al., 2002). Human pDCs were isolated from PBMC using the BDCA-4 
isolation kit (Miltenyi Biotec). Puriﬁ   ed pDCs were cultured for 16–20 h 
in RPMI 1640 supplemented with 10% FCS, GlutaMAX, kanamycin, and 
Na-pyruvate (all from Invitrogen). IL-3 (R&D Systems) was added to a ﬁ  nal 
Figure 9.  A model for the two-step activation by CpG-DNA. We propose 
that the recognition of A class CpG-DNA is a two-step process that can 
  begin at the plasma membrane (PM) by a TLR9-independent mechanism. 
We hypothesize the existence of a receptor, localized at the plasma 
  membrane, which is able to distinguish CpG- versus GpC-DNA. CpG-DNA 
stimulation of this receptor would activate two SFKs, Hck and Lyn, that 
would initiate a tyrosine phosphorylation cascade that can be fully inhib-
ited with the inhibitor PP2. SFK-mediated actin ﬁ  lament rearrangement is 
upstream of cell adhesion, spreading, and migration. One downstream 
  effector of the SFK pathway, Syk, interacts with TLR9. The second CpG-
  induced activation event occurs at the endosome when internalized 
CpG-DNA binds TLR9 and initiates the MyD88-dependent cascade that is 
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concentration of 20 ng/ml. Unless indicated in the ﬁ  gure legends, type I 
interferon levels in culture supernatants were measured by evaluating the 
inhibition of Daudi cell proliferation with reference to a standard IFN-α 
curve (Nederman et al., 1990).
Murine B cells were obtained by negative selection, removing at-
tached cells and then using anti-Thy1.2 magnetic beads (Dynal). Murine 
bone marrow–derived DCs were generated from bone marrow progenitors 
as described by Lutz et al. (1999). In brief, freshly prepared bone marrow 
cells were cultured in RPMI 1640 medium supplemented with 10% heat-
  inactivated FCS, 2 mM L-glutamine, 10 mM Hepes buffer, 50 μg/ml peni-
cillin, and nonessential amino acids in the presence of 200 U/ml GM-CSF 
(granulocyte-macrophage colony-stimulating factor; Sigma-Aldrich). 
  Cultures were supplemented with GM-CSF on days 3 and 8. Murine-elicited 
macrophages were obtained by peritoneal lavage 4 d after peritoneal in-
jection of 2 ml of thioglycollate broth (Sigma-Aldrich). They were washed 
three times in FCS-supplemented serum and then plated. 1 h later, unat-
tached cells were discarded. For biochemistry, cells were cultured for 24 h 
in DME supplemented with 0.5% FCS, 2 mM L-glutamine, 50 ng/ml IFN-γ, 
and antibiotics and then stimulated as indicated in ﬁ  gure legends.
Antibodies and reagents
Anti-p65, anti–IκB-α, anti-Cbl, anti-Vav, anti-Syk, anti-Syk anti-Hck, and 
anti-Lyn were obtained from Santa Cruz Biotechnology, Inc. Akt and P-Y-Akt 
were from Cell Signaling. Monoclonal anti-Flag (M2) was purchased from 
Sigma-Aldrich. Anti-Pyk2 was purchased from BD Biosciences, and anti-
pTyr (clone 4G10), anti-paxillin, anti-vinculin, and anti-talin antibodies were 
purchased from Upstate Biotechnology. Hoescht 33342, FITC-phalloidin, 
FluoSpheres polystyrene microspheres (10 μm for RAW cells and 15 μm 
in diameter for peritoneal macrophages), red ﬂ   uorescent (580/605), 
and TOPRO-3 were obtained from Invitrogen. Herbimycin, Syk inhibitor, 
PP2, and PP3 were purchased from Calbiochem. Chloroquine, quinacrine, 
lipopolysaccharide, and red blood cell lysis buffer were obtained from 
Sigma-Aldrich. Oligonucleotides were obtained from GenBase and, unless 
indicated otherwise, were used at 1 μg/ml. The human stimulatory se-
quences used were as follows: human ODN2216, referred to as CpG 
gggggACGATCGTCgggggg, and a control ODN, GpC gggggAGCAT-
GCTgggggg. We used the B class CpG oligo 2006 tcgtcgttttgtcgttttgtcgt. 
For stimulating murine macrophages and DCs, we used as stimulatory 
CpG ODN1585 ggG  G  T  C  A  A  C  G  T  T  G  A  G  ggggg, and as control, GpC 
ggG  G  T  C  A  A  G  C  T  T  G  A  G  ggggg. We also used ODN1668 tccatgacgttcct-
gatgct. For mouse B cell stimulation, we used mouse-selective CpG gccat-
gacgttgagct. Capital letters for ODN sequences indicate regular 
phosphodiester-linked nucleotides, and lowercase letters indicate phosphoro  -
thioate-linked nucleotides.
Cell transfection
Human Hck and Lyn siRNA SMARTpools were obtained from Dharmacon. 
THP-1 cells were transfected with 100 nM of each siRNA or in combination 
using a Nucleofector and Kit V according to the manufacturer’s recommen-
dations (Amaxa Biosystems). Cells were cultured for 48 h and then ana-
lyzed in adhesion and cytokine assays.
Cell lysis and immunoblotting
Cells were lysed in RIPA buffer for 30 min on ice (50 mM Tris, pH 7.5, 
150 mM NaCl, 1% Triton X-100, 0.5% DOC, 0.1% SDS, protease inhibitor 
tablet [Roche], 1 mM NaF, 1 mM Na3VO4, and 1 mM PMSF). After centrifu-
gation (20,000 g, 10 min, 4°C), supernatants were analyzed by SDS-
PAGE. For anti-paxillin, anti-talin, and anti-vinculin immunoprecipitations, 
cells were lysed directly in sample buffer containing 1% SDS, boiled, and 
diluted 10-fold with 1% Triton X-100 containing lysis buffer.
Immunoﬂ  uorescence
Cells were stimulated as indicated in ﬁ  gure legends and then ﬁ  xed with 
4% paraformaldehyde in PBS, washed twice with PBS, and blocked with 2% 
BSA in PBS for 2 h. All incubations and washes were performed in 0.5% 
BSA and 0.1% Triton X-100 in PBS. Antibody staining was performed at 
37°C in a moist chamber for 1 h. F-actin was stained with FITC-phalloidin 
for 20 min, cells were washed twice in PBS, and nuclei were stained with 
TOPRO-3 for 20 min. Samples were mounted, and images were captured 
with a confocal microscope (IX70; Olympus) using the uPlanApo 100×/1.35 
lens and Fluoview 2.0 (Olympus) program. For immobilized ODN micro-
sphere cell binding, 10
6 microsphere beads were coated with a 1-mg/ml 
solution of GpC or CpG-ODN overnight and then washed four times in 
culture medium. Coated microspheres (10-μm diameter for RAW cells or 
15 μm for peritoneal macrophages) were added to cells in culture at a 
  microsphere/cell ratio of 3:1. Cells were ﬁ  xed after an incubation of 20 min.
Adhesion assays
10
5 cells/well were plated in 96-well plates. After the indicated treatments, 
cells were ﬁ  xed with 4% paraformaldehyde in PBS for 5 min. Unattached 
cells were removed by washing six times with PBS. The nuclei of attached cells 
were stained with Hoechst dye for 10 min. Cells were then visualized   using 
a 5× magniﬁ  cation on a ArrayScanII (Cellomics), and the number of nuclei 
per ﬁ  eld were counted using the manufacturer’s software. For ﬁ  nal analysis, 
a mean of 36 ﬁ  elds from at least four different wells were counted.
ELISA
Single-cell splenocyte suspensions or human pDCs (5 × 10
5 cells/well) 
were stimulated for 24 h with 1 μM ODN. Supernatants were collected, 
and IL-6 or IFN-α (R&D system) were measured by ELISA according to the 
manufacturer’s instructions.
Flow cytometry
Splenocytes were stained and analyzed on a FACScalibur (Becton 
  Dickinson). For measuring up-regulation of B cell activation markers, cell 
surface expression of CD40 and CD69 were analyzed on gated B-220–
positive cells. The cells were stained with FITC-conjugated anti-CD40, anti-
CD69, and allophycocyanin-conjugated anti-B220 from BD Biosciences.
Online supplemental material
Fig. S1 shows the effect of the microﬁ  lament-disrupting drugs cytochalasin D, 
latrunculin A, and jasplakinolide on CpG-induced adhesion. Fig. S2 shows 
that chloroquine and quinacrine are unable to block CpG-induced cell 
motility. Fig. S3 shows that MyD88
−/− mice are unresponsive to CpG as 
measured as the secretion of IL-6 or the up-regulation of the plasma mem-
brane level of CD40 and CD69. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200508058/DC1.
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